$60m For Mexico’s Genomma From World Bank Group’s Private Sector Arm
The Investment Aims To Improve Medicines Access In Latin America And The Caribbean Region
IFC, the private sector arm of the World Bank Group, has loaned $60m to Mexican Pharmaceutical Genomma, building on its long track record in Latin American health investments.
You may also be interested in...
This article compiles all the data from Generics Bulletin’s 2022 ranking of the top 50 generics and biosimilars companies, including additional details of how the financial figures stack up.
Mexican OTC medicines and personalcare specialist Genomma Lab has secured an investment package of almost US$100 million (€85 million) to help fund the ongoing construction of a production plant in its home country.
Hyloris’ partner AFT has signed an exclusive licensing and distribution agreement with Salus Pharmaceuticals covering nine central and eastern European countries. Meanwhile, Hyloris has also struck an in-licensing deal for a new blood phosphorus deficiency treatment.